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Background: Radioiodine and Tc-99 m pertechnetate scans are routinely relied upon to detect metastasis in papillary
thyroid cancer; false-positive scans are relatively rare. To our knowledge, no published reports exist of sarcoidosis causing
such selectively false-positive scans.
Methods: We present a case of a 41-year-old woman with known metastatic papillary thyroid cancer (T1bN1aMx)
in whom sarcoidosis-affected cervical and mediastinal lymph nodes demonstrated uptake of thyroid-targeting
radionuclides. Only the minority of these nodes demonstrated radionuclide uptake, raising the suspicion of adjacent or
coexisting sarcoid and metastatic involvement. Selective uptake of thyroid-targeted radionuclides by isolated sarcoidosis
is, to our knowledge, a previously undocumented occurrence.
Results: Biopsies of uptake-negative mediastinal nodes revealed sarcoidosis. Pathology from a subsequent neck
dissection excising uptake-positive cervical nodes also showed sarcoidosis, with no coinciding malignancy.
Conclusions: We document a case of sarcoidosis causing a selectively false-positive thyroid scintigraphy scan. It
is useful for clinicians to be aware of potential false-positives and deceptive patterns on radionuclide scans
when managing patients with both well-differentiated thyroid cancer and a co-existing disease affecting the
nodal basins draining the thyroid gland.
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Papillary thyroid cancer is a relatively common malig-
nancy, occurring with markedly increasing incidence in
developed countries [1]. The approach to treatment has
been fairly consistent for decades; in the majority of
cases, the paradigm continues to be surgery followed by
radioactive iodine treatment of residual or metastatic tis-
sue [2]. Radioiodine (particularly 131I) scans are routinely
relied upon to detect metastasis because of their per-
ceived specificity in identifying normal and malignant
thyroid tissue. Detection hinges on retention of the abil-
ity to concentrate and store iodine by well-differentiated
thyroid malignancies [3].* Correspondence: modell@toh.on.ca
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scans (localized to the head and neck) are often used in
place of radioiodine scans for identifying functional thy-
roid tissue, with only occasional result discrepancies [4].
Pertechnetate is trapped by the same sodium-iodine
symporter as radioiodine, but is washed out relatively
rapidly as it is not stored by follicular cells [5]. Pertech-
netate thyroid scans carry the advantages of lower radi-
ation doses, faster results, and greater accessibility
compared to 131I [6]. 131I is the preferred radionuclide
for whole body imaging, where a longer half-life is
desirable [7].
False-positive radioiodine scans are rare. Numerous
artifacts and physiologic variants are known to consist-
ently take up radioiodine but are easily discounted by
experienced nuclear medicine physicians. Several non-
thyroidal disease processes have been noted to demon-
strate uptake in less predictable patterns. These includehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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infections [3,8]. False-positive pertechnetate thyroid
scans are also uncommon. As the pertechnetate ion be-
haves similar to iodide, it displays analogous physiologic
and artifactual uptake patterns (ex. by salivary glands,
gastric mucosa) [9].
Sarcoidosis is a systemic disorder of unknown etiology,
characterized by development of non-caseating granu-
lomas in affected organs. Lung and thoracic lymph node
involvement are most common, though many other sites
can be involved. Clinical presentation is not uncom-
monly an incidental finding on imaging conducted for
other purposes. Sarcoidosis exhibits a predilection for
adults under 40 and specific racial groups, particularly
those of African descent [10]. To our knowledge,
sarcoidosis has not previously been described in the lit-
erature as a disease entity demonstrating conclusive
radioiodine or pertechnetate uptake. A report exists of
sarcoidosis mimicking a suprasellar tumour on a per-
technetate brain scan, but the increased uptake was at-
tributed to general disruption of the blood–brain-barrier,
not to specific uptake by sarcoid tissue [11].
Here we document a case of sarcoidosis causing a
false-positive radionuclide scan in a patient with papil-




A 41-year-old Caucasian woman was referred with a
left-sided thyroid nodule. Fine-needle aspiration revealed
a diagnosis of papillary thyroid carcinoma; the patient
thus underwent a total thyroidectomy and left central
nodal dissection. Pathology showed multifocal papillary
thyroid carcinoma and one positive lymph node (AJCC
Stage T1bN1aMx). In addition, epithelioid granulomasFigure 1 Corresponding SPECT and fused SPECT/CT images showing conc
image (right) demonstrating abnormal foci of accumulation of 99mTc04
− rad
the known thyroid tumor. [Dotted line (−−-) indicates submandibular gland
the area of concern in the lateral jugular chain]. No appreciable 99mTc04
− up
disease was identified on plain CT-Neck.were identified within this node. This was reported as
suggesting a concurrent infectious process, though the
possibility of sarcoidosis was not ruled out.
In preparation for postoperative radioiodine remnant
ablation, pre-ablation imaging was performed with
Tc-99 m pertechnetate thyroid scanning. The patient
was injected with 370 MBq (10 mCi) of Tc-99 m pertech-
netate IV. Imaging began 15 minutes post-injection.
Static images were acquired using a Siemens Symbia T1
gamma camera with a pinhole collimator of 4 mm aper-
ture (matrix 128x128, zoom factor 2). A first static image
was acquired over 108 seconds at 14.9 cm from the neck,
with the patient supine and markers at the sternal notch
and thyroid cartilage. A second static image was acquired
from the same distance over 300 seconds. A third, mag-
nified, image was obtained at a distance of 3 cm from the
patient's neck.
SPECT/CT of the same area was performed over a
180° arc (clockwise rotation), using 128 projections
(64 views x dual heads) at 12 s per view. Images
were acquired into a 128x128 matrix at a zoom factor of 1,
using a step-and-shoot rotation with an auto-continuing
non-circular orbit. Scout CT was obtained (30 mA,
130 kV, scan time 0.8 s), followed by routine CT at a slice
thickness of 5 mm, effective current of 17 mA, and voltage
of 130 kV.
The radionuclide imaging showed uptake-positive
lesions along the left internal jugular chain, highly
suggestive of metastases (Figure 1). At that time,
total body 131I uptake was elevated at 7.4% (expected
normal < 5%), and un-stimulated (TSH 10.28 mU/L)
serum thyroglobulin was 5.5 pmol/L. Plain CT of the
neck showed extensive nodal disease in the neck, as well
as in the mediastinum. Notably, unlike the cervical
nodes, these mediastinal nodes had not shown appre-
ciable uptake on the pertechnetate thyroid scan. CT oferning cervical lesions. SPECT coronal slice (left) and fused SPECT/CT
ioactive tracer in a lymph node of the left jugular chain, ipsilateral to
; small dotted arrow indicates thyroid remnant; large arrow indicates
take is observed in the superior mediastinum, where extensive nodal
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hilar lymphadenopathy. Percutaneous biopsies of the me-
diastinal and pulmonary nodes demonstrated findings
consistent with a diagnosis of sarcoidosis and no coincid-
ing malignancy.
The patient was presented with the option of fine-
needle aspiration biopsy of the scan-positive cervical
nodes as a means of confirming or discounting their
metastatic etiology (versus being purely additional foci
of sarcoidosis) before deciding whether to proceed with
selective neck dissection. It was agreed that a negative
FNAB would not be sufficiently reassuring to justify no
further surgery, given the suspicious location, the ab-
sence of previous reports of convincing pertechnetate or
radioiodine uptake by sarcoid tissue, and, moreover, the
selective uptake of pertechnetate by the cervical nodes
alone.
Left lateral neck dissection was therefore performed
without complication. Final surgical pathology showed
all level II, III, IV nodes negative for malignancy, and
level IV nodes positive for granulomatous lymphadenitis
compatible with sarcoidosis. The patient underwent
radioiodine ablation in October 2009. Follow-up imaging
(131I whole body scanning) to date has been normal, and
there has been no clinical evidence of malignancy re-
lapse in the primary site or the neck.
Discussion
Papillary thyroid cancer, constituting >90% of thyroid
malignancies [2], is a relatively common disease in
young, Caucasian women [12]. Radioiodine and Tc-99 m
pertechnetate scans are relied upon for detection of
recurrence and metastasis because of their perceived
specificity for normal and well-differentiated malignant
thyroid tissue. 131I whole body scans have become the
particular scan of choice in monitoring for spread and
relapse [3].
Survival rates for papillary cancer are high, but follow-
up including appropriate and timely management of
recurrence is important to avoid uncontrolled loco-
regional disease. The regional metastatic pattern for pap-
illary cancer is fairly predictable, with initial spread to
central compartment (level VI) nodes, followed typically
by ipsilateral jugular nodes, with level III and IV involve-
ment in particular being more common than level II
[13,14]. Nodal involvement is frequently encountered
[2], thus ipsilateral cervical nodes deserve significant
attention during work-up for metastatic spread. In our
patient, the identification of new lesions along the length
of the internal jugular chain ipsilateral to her thyroid
nodule and lone metastatic central node was highly
suspicious for malignant spread. Notably, patients with
sarcoidosis have been observed to develop sarcoid-
granulomas in cervical nodes [10]. Had radionuclideuptake been consistent amongst the cervical, medias-
tinal, and pulmonary nodes (either all positive, or all
negative), cervical lymphadenopathy attributable to
sarcoidosis would have been a reasonable alternative
diagnosis.
Ultimately, uptake of a thyroid-targeted radionuclide
by our patient’s cervical lesions and not by the medias-
tinal nodes known to be affected by sarcoidosis was the
most convincing factor supporting our anticipation of
papillary cancer spread. Further, with no previous evi-
dence of sarcoidosis causing false-positive scans, and no
immediately obvious physiologic reason to expect per-
technetate or iodine uptake by sarcoid granulomas, our
patient’s underlying sarcoidosis was not initially a con-
vincing cause for her scan-positive lesions.
Conclusions
The unexpected finding of sarcoidosis as the pathology
underlying our patient’s scan-positive cervical lesions is,
to our knowledge, the first report of sarcoidosis demon-
strating uptake of the radionuclides used in assessing
thyroid tissue. For surgeons using nuclear imaging to
work-up thyroid malignancy in patients with sarcoidosis,
this is an important phenomenon, demonstrating a need
to be cognizant of the possibility for false-positives.
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